Browse result page of B3Pdb
The total number entries retrieved from this search are 92, scroll left/right for detailed information.
| B3pdbIDb3pdb_0001 | PEPTIDE NAMEMtfpep | PEPTIDE SEQUENCE (1-letter)DSSHAFTLDELR | PEPTIDE SEQUENCE (3-letter)AspSerSerHisAlaPheThrLeuAspGluLeuArg | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Polyethylene glycol (PEG)4 linker | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH12 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEMelanotransferrin | SMILESN[C@@]([H])(CC(=O)O)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CC1=CN=C-N1)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(Cc1ccccc1)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(=O)O)C(=O)N[C@@]([H])(CCC(=O)O)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)O | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELMice | In vivo CONCENTRATION2 MTfpep per NIP228 antibody | In vivo MODE OF DELIVERYIntravenous | In vivo METHOD3D confocal fluorescence microscopy | In vivo RESULTTwo times greater fractional fluorescence was measured in the brain parenchyma. | ACTIONIt delivers a protein-based interleukin 1 receptor antagonist across the BBB and ameliorates | TRANSPORT TYPETranscytosis | SUBCELLULAR LOCALISATIONSurface of normal brain endothelial cells, the main constituent of the BBB, and is able to cross thr | COMBINATIONSuccessfully delivers therapeutic amounts of an an | PHYSICAL CONDITIONNeuropathic pain | RESPONSEStability/half life | RESULT5.5 days | LABELNA | PMID 29845881 |
| B3pdbIDb3pdb_0005 | PEPTIDE NAMER-Rfa | PEPTIDE SEQUENCE (1-letter)SLKPAANLPLRF | PEPTIDE SEQUENCE (3-letter)SerLeuLysProAlaAlaAsnLeuProLeuArgPhe | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATION5(6)-carboxyfluorescein attched to peptide | PEPTIDE LENGTH12 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEDodeca-neuropeptide (SLKPAANLPLRF) of frog brain. | SMILESN[C@@]([H])(CO)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(Cc1ccccc1)C(=O)O | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELRat primary cortical neurons | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYIntraperitoneal | In vivo METHODFourier Transform Infrared Spectroscopy | In vivo RESULTInhibition of Aβ fibrillation | ACTIONIt inhibits Aβ fibrillization, moderately binds with tubulin and promotes tubulin polymerization as | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONAlzheimer’s disease | RESPONSENA | RESULTNA | LABELNA | PMID 30408415 |
| B3pdbIDb3pdb_0038 | PEPTIDE NAMEApoB11 | PEPTIDE SEQUENCE (1-letter)RLTRKRGLKLA | PEPTIDE SEQUENCE (3-letter)ArgLeuThrArgLysArgGlyLeuLysLeuAla | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION 5 Gly (G) and 9 Arg (R) amino acids to the C-termi | CHEMICAL MODIFICATIONCoupled with a 9-amiNA acid arginine linker | PEPTIDE LENGTH11 | PEPTIDE CONFORMATIONNA | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEApoB38 peptide | SMILESN[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)NCC(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)O | CELL LINEMouse cholinergic cell line Neuro2A (N2A) | In vitro CONCENTRATION100000 cells/well | In vitro METHODLaser scanning confocal microscopy | In vitro RESULTIt crosses the BBB with conguagted siRNA for alpha-syn. | ANIMAL MODELTransgenic Mice | In vivo CONCENTRATION50 microgram | In vivo MODE OF DELIVERYIntraperitoneal | In vivo METHODLaser scanning confocal microscopy | In vivo RESULTIt can transport siα-syn across the BBB as a therapeutic option for synucleinopathies. | ACTIONIt showed reduced accumulation of α-syn associated with amelioration of the neurodegenerative and i | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNeurons and glial cellsexhibiting α-syn accumulation | COMBINATIONCombined with siRNA for alpha-syn | PHYSICAL CONDITIONLewy body disease | RESPONSENA | RESULTNA | LABELNA | PMID 30849508 |
| B3pdbIDb3pdb_0039 | PEPTIDE NAMEC2-9r | PEPTIDE SEQUENCE (1-letter)CDIFTNSRGKRA | PEPTIDE SEQUENCE (3-letter)CysAspIlePheThrAsnSerArgGlyLysArgAla | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION 4 Gly (G) and nine d-Arg (9r) residues to the Cter | CHEMICAL MODIFICATIONCoupled with a 9-amiNA acid arginine linker | PEPTIDE LENGTH12 | PEPTIDE CONFORMATIONNA | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDErhabdovirus glycoprotein | SMILESN[C@@]([H])(CS)C(=O)N[C@@]([H])(CC(=O)O)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(Cc1ccccc1)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(C)C(=O)O | CELL LINEMouse cholinergic cell line Neuro2A (N2A) | In vitro CONCENTRATION100000 cells/well | In vitro METHODLaser scanning confocal microscopy | In vitro RESULTIt crosses the BBB with conguagted siRNA for alpha-syn. | ANIMAL MODELTransgenic Mice | In vivo CONCENTRATION50 microgram | In vivo MODE OF DELIVERYIntraperitoneal | In vivo METHODLaser scanning confocal microscopy | In vivo RESULTIt can transport siα-syn across the BBB as a therapeutic option for synucleinopathies. | ACTIONIt showed reduced accumulation of α-syn associated with amelioration of the neurodegenerative and i | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNeurons and glial cellsexhibiting α-syn accumulation | COMBINATIONCombined with siRNA for alpha-syn | PHYSICAL CONDITIONLewy body disease | RESPONSENA | RESULTNA | LABELNA | PMID 30849508 |
| B3pdbIDb3pdb_0052 | PEPTIDE NAMEPhage clone 1.2 | PEPTIDE SEQUENCE (1-letter)VAARTGEIYVPW | PEPTIDE SEQUENCE (3-letter)ValAlaAlaArgThrGlyGluIleTyrValProTrp | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH12 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)NCC(=O)N[C@@]([H])(CCC(=O)O)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(C(C)C)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(CC(=CN2)C1=C2C=CC=C1)C(=O)O | CELL LINESH-SY5Y cells | In vitro CONCENTRATIONNA | In vitro METHODUHPLC-MS/MS | In vitro RESULTThe phage display adverses the BBB with the peptide. | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONPeptides bound specifically to primary endothelial cells and could traverse the BBB. | TRANSPORT TYPETranscytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with phage display | PHYSICAL CONDITIONNA | RESPONSEStability/half life | RESULT1.5 x 10e-6 cm/s | LABELNA | PMID 32079185 |
| B3pdbIDb3pdb_0053 | PEPTIDE NAMEPhage clone 1.3 | PEPTIDE SEQUENCE (1-letter)GLHTSATNLYLH | PEPTIDE SEQUENCE (3-letter)GlyLeuHisThrSerAlaThrAsnLeuTyrLeuHis | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH12 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESNCC(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC1=CN=C-N1)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC1=CN=C-N1)C(=O)O | CELL LINESH-SY5Y cells | In vitro CONCENTRATIONNA | In vitro METHODUHPLC-MS/MS | In vitro RESULTThe phage display adverses the BBB with the peptide. | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONPeptides bound specifically to primary endothelial cells and could traverse the BBB. | TRANSPORT TYPETranscytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with phage display | PHYSICAL CONDITIONNA | RESPONSEStability/half life | RESULT3.3 x 10e-7 cm/s | LABELNA | PMID 32079185 |
| B3pdbIDb3pdb_0054 | PEPTIDE NAMETfr1 | PEPTIDE SEQUENCE (1-letter)THRPPMWSPVWP | PEPTIDE SEQUENCE (3-letter)ThrHisArgProProMetTrpSerProValTrpPro | N-TERMINAL MODIFICATIONFAM is conjgated at the N-terminal | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH12 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])([C@]([H])(O)C)C(=O)N[C@@]([H])(CC1=CN=C-N1)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(CCSC)C(=O)N[C@@]([H])(CC(=CN2)C1=C2C=CC=C1)C(=O)N[C@@]([H])(CO)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CC(=CN2)C1=C2C=CC=C1)C(=O)N1[C@@]([H])(CCC1)C(=O)O | CELL LINEbEnd.3 cells | In vitro CONCENTRATIONNA | In vitro METHODImmunofluorescence microscopy | In vitro RESULTIt shows the permeability towards the BBB. | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONThese novel peptide conjugates have the capacity to act as promising brain shuttles | TRANSPORT TYPEReceptor-mediated transcytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 32055384 |
| B3pdbIDb3pdb_0072 | PEPTIDE NAMENeurotensin | PEPTIDE SEQUENCE (1-letter)ELYENKPRRPYIL | PEPTIDE SEQUENCE (3-letter)pGlu-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu-OH | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH13 | PEPTIDE CONFORMATIONTridecapeptide | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEbovine hypothalamus | SMILESN[C@@]([H])(CCC(=O)O)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CCC(=O)O)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CCCCN)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELAdult male Swiss-Webster mice | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODStudent's t-test (two-tailed) and Mann-Whitney U-test | In vivo RESULTNA | ACTIONNot able to cross the BBB in sufficient quantities to exert direct brain effects. Can modify the sed | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 406965 |
| B3pdbIDb3pdb_0135 | PEPTIDE NAMEG23 | PEPTIDE SEQUENCE (1-letter)HLNILSTLWKYR | PEPTIDE SEQUENCE (3-letter)HisLeuAsnIleLeuSerThrLeuTrpLysTyrArg | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH12 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEPhage display of prion proteins | SMILESNA | CELL LINEhCMEC/D3 | In vitro CONCENTRATIONNA | In vitro METHODFluoroscent measure | In vitro RESULTG23 peptide can cross basal layer | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPETranscytosis as well as BBB penetration | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 22536790 |
| B3pdbIDb3pdb_0136 | PEPTIDE NAMEG23 | PEPTIDE SEQUENCE (1-letter)HLNILSTLWKYR | PEPTIDE SEQUENCE (3-letter)HisLeuAsnIleLeuSerThrLeuTrpLysTyrArg | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH12 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEPhage display of prion proteins | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYIntravenous | In vivo METHODRadioimaging | In vivo RESULT0.052 + 0.019 of fluoroscent measured in btain tissue after 4 hours | ACTIONNA | TRANSPORT TYPETranscytosis as well as BBB penetration | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 22536790 |
| B3pdbIDb3pdb_0137 | PEPTIDE NAMEG23 | PEPTIDE SEQUENCE (1-letter)HLNILSTLWKYR | PEPTIDE SEQUENCE (3-letter)HisLeuAsnIleLeuSerThrLeuTrpLysTyrArg | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH12 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEPhage display of prion proteins | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYIntravenous | In vivo METHODRadioimaging | In vivo RESULT0.047 + 0.031 of fluoroscent measured in btain tissue after 24 hours | ACTIONNA | TRANSPORT TYPETranscytosis as well as BBB penetration | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 22536790 |
| B3pdbIDb3pdb_0138 | PEPTIDE NAMEScr-G23 | PEPTIDE SEQUENCE (1-letter)KISHLLNYRTWL | PEPTIDE SEQUENCE (3-letter)LysIleSerHisLeuLeuAsnTyrArgThrTrpLeu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH12 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEPhage display of prion proteins | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYIntravenous | In vivo METHODRadioimaging | In vivo RESULT0.013 + 0.006 of fluoroscent measured in btain tissue after 4 hours | ACTIONNA | TRANSPORT TYPETranscytosis as well as BBB penetration | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 22536790 |
| B3pdbIDb3pdb_0139 | PEPTIDE NAMEScr-G23 | PEPTIDE SEQUENCE (1-letter)KISHLLNYRTWL | PEPTIDE SEQUENCE (3-letter)LysIleSerHisLeuLeuAsnTyrArgThrTrpLeu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH12 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEPhage display of prion proteins | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYIntravenous | In vivo METHODRadioimaging | In vivo RESULT0.008 + 0.002 of fluoroscent measured in btain tissue after 24 hours | ACTIONNA | TRANSPORT TYPETranscytosis as well as BBB penetration | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 22536790 |
| B3pdbIDb3pdb_0147 | PEPTIDE NAMEGoldnanoparticle con | PEPTIDE SEQUENCE (1-letter)THRPPMWSPVWP | PEPTIDE SEQUENCE (3-letter)ThrHisArgProProMetTrpSerProValTrpPro | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONConjugated with CLPFFD goldnaNAparticle | PEPTIDE LENGTH12 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELAdult Sprague-Dawley rats | In vivo CONCENTRATION1.86 mg/Kg | In vivo MODE OF DELIVERYIntraperitoneal | In vivo METHODInstrumental neutron activation analysis and Nissl staining | In vivo RESULTConjugate was found to cross blodd brain barrier; does not effect mice survival; no toxicity as meas | ACTIONNA | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONAlzheimer | RESPONSENA | RESULTNA | LABELNA | PMID 22795856 |
| B3pdbIDb3pdb_0160 | PEPTIDE NAMEASA-Tat | PEPTIDE SEQUENCE (1-letter)YGRKKRRQRRR | PEPTIDE SEQUENCE (3-letter)TyrGlyArgLysLysArgArgGlnArgArgArg | N-TERMINAL MODIFICATIONConjugated with ASA drug | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH11 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINECHO cell line | In vitro CONCENTRATION2.5 microgram/ ml | In vitro METHODcellular uptake assay | In vitro RESULT 12.6 % cellular uptake | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPETransendocytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONLysosomal disorder | RESPONSENA | RESULTNA | LABELNA | PMID 24573272 |
| B3pdbIDb3pdb_0165 | PEPTIDE NAMEASA-Tat | PEPTIDE SEQUENCE (1-letter)YGRKKRRQRRR | PEPTIDE SEQUENCE (3-letter)TyrGlyArgLysLysArgArgGlnArgArgArg | N-TERMINAL MODIFICATIONConjugated with ASA drug | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH11 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINEbEND cell line | In vitro CONCENTRATION2.5 microgram/ ml | In vitro METHODcellular uptake assay | In vitro RESULT 16.6 % cellular uptake | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPETransendocytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONLysosomal disorder | RESPONSENA | RESULTNA | LABELNA | PMID 24573272 |
| B3pdbIDb3pdb_0170 | PEPTIDE NAMEASA-Tat | PEPTIDE SEQUENCE (1-letter)YGRKKRRQRRR | PEPTIDE SEQUENCE (3-letter)TyrGlyArgLysLysArgArgGlnArgArgArg | N-TERMINAL MODIFICATIONConjugated with ASA drug | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH11 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINEPBCECs cell line | In vitro CONCENTRATION0.02% cells were added | In vitro METHODBasolateral screening assay | In vitro RESULT100% transfer | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEBasolateral | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONLysosomal disorder | RESPONSENA | RESULTNA | LABELNA | PMID 24573272 |
| B3pdbIDb3pdb_0177 | PEPTIDE NAMEParent peptide | PEPTIDE SEQUENCE (1-letter)THRPPMWSPVWP | PEPTIDE SEQUENCE (3-letter)ThrHisArgProProMetTrpSerProValTrpPro | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amidated | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH12 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINERat astrocyte | In vitro CONCENTRATION50 micromolar | In vitro METHODHPLC, MALDI-TOF to analyze the peptide transport and apparent permeability | In vitro RESULT12.5+/- 3.4 apparent permeability | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEcan transport cargo | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 25650865 |
| B3pdbIDb3pdb_0178 | PEPTIDE NAMEN-methylaed parent p | PEPTIDE SEQUENCE (1-letter)T(Nme)H(Nme)RPPM(Nme)WSPVWP | PEPTIDE SEQUENCE (3-letter)NA | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amidated | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH12 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINERat astrocyte | In vitro CONCENTRATION50 micromolar | In vitro METHODHPLC, MALDI-TOF to analyze the peptide transport and apparent permeability | In vitro RESULT9.9+/- 1.6 apparent permeability | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEcan transport cargo | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 25650865 |
| B3pdbIDb3pdb_0179 | PEPTIDE NAMEEnatiomeric parent p | PEPTIDE SEQUENCE (1-letter)THRPPMWSPVWP | PEPTIDE SEQUENCE (3-letter)ThrHisArgProProMetTrpSerProValTrpPro | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amidated | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH12 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINERat astrocyte | In vitro CONCENTRATION50 micromolar | In vitro METHODHPLC, MALDI-TOF to analyze the peptide transport and apparent permeability | In vitro RESULT14.5+/- 2.0 apparent permeability | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEcan transport cargo | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 25650865 |
| B3pdbIDb3pdb_0180 | PEPTIDE NAMERetro-enantiomeric p | PEPTIDE SEQUENCE (1-letter)PWVPSWMPPRHT | PEPTIDE SEQUENCE (3-letter)ProTrpValProSerTrpMetProProArgHisThr | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amidated | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH12 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINERat astrocyte | In vitro CONCENTRATION50 micromolar | In vitro METHODHPLC, MALDI-TOF to analyze the peptide transport and apparent permeability | In vitro RESULT21.5+/- 2.8 apparent permeability | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEcan transport cargo | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 25650865 |
| B3pdbIDb3pdb_0181 | PEPTIDE NAMEParent peptide | PEPTIDE SEQUENCE (1-letter)THRPPMWSPVWP | PEPTIDE SEQUENCE (3-letter)ThrHisArgProProMetTrpSerProValTrpPro | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amidated | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH12 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINERat astrocyte | In vitro CONCENTRATION50 micromolar | In vitro METHODHPLC, MALDI-TOF to analyze the peptide transport and apparent permeability | In vitro RESULT14.9+/- 2.5 apparent permeability | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEcan transport cargo | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 25650865 |
| B3pdbIDb3pdb_0182 | PEPTIDE NAMEN-methylaed parent p | PEPTIDE SEQUENCE (1-letter)T(Nme)H(Nme)RPPM(Nme)WSPVWP | PEPTIDE SEQUENCE (3-letter)NA | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amidated | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH12 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINERat astrocyte | In vitro CONCENTRATION50 micromolar | In vitro METHODHPLC, MALDI-TOF to analyze the peptide transport and apparent permeability | In vitro RESULT11.7+/- 6.4 apparent permeability | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEcan transport cargo | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 25650865 |
| B3pdbIDb3pdb_0183 | PEPTIDE NAMEEnatiomeric parent p | PEPTIDE SEQUENCE (1-letter)THRPPMWSPVWP | PEPTIDE SEQUENCE (3-letter)ThrHisArgProProMetTrpSerProValTrpPro | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amidated | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH12 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINERat astrocyte | In vitro CONCENTRATION50 micromolar | In vitro METHODHPLC, MALDI-TOF to analyze the peptide transport and apparent permeability | In vitro RESULT17.2+/- 1.2 apparent permeability | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEcan transport cargo | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 25650865 |
| B3pdbIDb3pdb_0184 | PEPTIDE NAMERetro-enantiomeric p | PEPTIDE SEQUENCE (1-letter)PWVPSWMPPRHT | PEPTIDE SEQUENCE (3-letter)ProTrpValProSerTrpMetProProArgHisThr | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amidated | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH12 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINERat astrocyte | In vitro CONCENTRATION50 micromolar | In vitro METHODHPLC, MALDI-TOF to analyze the peptide transport and apparent permeability | In vitro RESULT25.1+/- 3.0 apparent permeability | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEcan transport cargo | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 25650865 |
| B3pdbIDb3pdb_0185 | PEPTIDE NAMEParent peptide | PEPTIDE SEQUENCE (1-letter)THRPPMWSPVWP | PEPTIDE SEQUENCE (3-letter)ThrHisArgProProMetTrpSerProValTrpPro | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amidated | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH12 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINERat astrocyte | In vitro CONCENTRATION50 micromolar | In vitro METHODPAMPA method for cargo delivery and transportation efficiency | In vitro RESULT16.2+/- 1.3 apparent permeability | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEcan transport cargo | SUBCELLULAR LOCALISATIONNA | COMBINATIONcarboxyfluoroscein | PHYSICAL CONDITIONAntiallergic drug | RESPONSENA | RESULTNA | LABELNA | PMID 25650865 |
| B3pdbIDb3pdb_0186 | PEPTIDE NAMEN-methylaed parent p | PEPTIDE SEQUENCE (1-letter)T(Nme)H(Nme)RPPM(Nme)WSPVWP | PEPTIDE SEQUENCE (3-letter)NA | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amidated | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH12 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINERat astrocyte | In vitro CONCENTRATION50 micromolar | In vitro METHODPAMPA method for cargo delivery and transportation efficiency | In vitro RESULT0.14.7+/- 0.01 apparent permeability | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEcan transport cargo | SUBCELLULAR LOCALISATIONNA | COMBINATIONH-a(Nme)f-D-2-nal-vlkk-Nh2 | PHYSICAL CONDITIONAntialzheimer peptide | RESPONSENA | RESULTNA | LABELNA | PMID 25650865 |
| B3pdbIDb3pdb_0187 | PEPTIDE NAMEEnatiomeric parent p | PEPTIDE SEQUENCE (1-letter)THRPPMWSPVWP | PEPTIDE SEQUENCE (3-letter)ThrHisArgProProMetTrpSerProValTrpPro | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amidated | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH12 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINERat astrocyte | In vitro CONCENTRATION50 micromolar | In vitro METHODPAMPA method for cargo delivery and transportation efficiency | In vitro RESULT0.19.2+/- 0.07 apparent permeability | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEcan transport cargo | SUBCELLULAR LOCALISATIONNA | COMBINATIONiron oxide nanoparticle | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 25650865 |
| B3pdbIDb3pdb_0188 | PEPTIDE NAMERetro-enantiomeric p | PEPTIDE SEQUENCE (1-letter)PWVPSWMPPRHT | PEPTIDE SEQUENCE (3-letter)ProTrpValProSerTrpMetProProArgHisThr | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amidated | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH12 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINERat astrocyte | In vitro CONCENTRATION50 micromolar | In vitro METHODPAMPA method for cargo delivery and transportation efficiency | In vitro RESULT0.27+/- 0.03 apparent permeability | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEcan transport cargo | SUBCELLULAR LOCALISATIONNA | COMBINATIONQuantum dots | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 25650865 |
| B3pdbIDb3pdb_0189 | PEPTIDE NAMEParent peptide | PEPTIDE SEQUENCE (1-letter)THRPPMWSPVWP | PEPTIDE SEQUENCE (3-letter)ThrHisArgProProMetTrpSerProValTrpPro | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amidated | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH12 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINERat astrocyte | In vitro CONCENTRATION50 micromolar | In vitro METHODPAMPA method for cargo delivery and transportation efficiency | In vitro RESULT17.1+/- 2.6 transport efficiency | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEcan transport cargo | SUBCELLULAR LOCALISATIONNA | COMBINATIONcarboxyfluoroscein | PHYSICAL CONDITIONAntiallergic drug | RESPONSENA | RESULTNA | LABELNA | PMID 25650865 |
| B3pdbIDb3pdb_0190 | PEPTIDE NAMEN-methylaed parent p | PEPTIDE SEQUENCE (1-letter)T(Nme)H(Nme)RPPM(Nme)WSPVWP | PEPTIDE SEQUENCE (3-letter)NA | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amidated | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH12 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINERat astrocyte | In vitro CONCENTRATION50 micromolar | In vitro METHODPAMPA method for cargo delivery and transportation efficiency | In vitro RESULT0.20+/- 0.01 transport efficiency | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEcan transport cargo | SUBCELLULAR LOCALISATIONNA | COMBINATIONH-a(Nme)f-D-2-nal-vlkk-Nh2 | PHYSICAL CONDITIONAntialzheimer peptide | RESPONSENA | RESULTNA | LABELNA | PMID 25650865 |
| B3pdbIDb3pdb_0191 | PEPTIDE NAMEEnatiomeric parent p | PEPTIDE SEQUENCE (1-letter)THRPPMWSPVWP | PEPTIDE SEQUENCE (3-letter)ThrHisArgProProMetTrpSerProValTrpPro | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amidated | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH12 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINERat astrocyte | In vitro CONCENTRATION50 micromolar | In vitro METHODPAMPA method for cargo delivery and transportation efficiency | In vitro RESULT0.22+/- 0.05 transport efficiency | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEcan transport cargo | SUBCELLULAR LOCALISATIONNA | COMBINATIONiron oxide nanoparticle | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 25650865 |
| B3pdbIDb3pdb_0192 | PEPTIDE NAMERetro-enantiomeric p | PEPTIDE SEQUENCE (1-letter)PWVPSWMPPRHT | PEPTIDE SEQUENCE (3-letter)ProTrpValProSerTrpMetProProArgHisThr | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amidated | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH12 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINERat astrocyte | In vitro CONCENTRATION50 micromolar | In vitro METHODPAMPA method for cargo delivery and transportation efficiency | In vitro RESULT0.031+/- 0.02 transport efficiency | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEcan transport cargo | SUBCELLULAR LOCALISATIONNA | COMBINATIONQuantum dots | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 25650865 |
| B3pdbIDb3pdb_0197 | PEPTIDE NAMEBacteriophage derive | PEPTIDE SEQUENCE (1-letter)RRPAPLIMFRMI | PEPTIDE SEQUENCE (3-letter)ArgArgProAlaProLeuIleMetPheArgMetIle | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH12 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDET7 Bacteiophage derived | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELMale wistar mice | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONCan cross BBB as well as Blood CSF barrier | TRANSPORT TYPETransendocytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONAlzheimer | RESPONSENA | RESULTNA | LABELNA | PMID 26411801 |
| B3pdbIDb3pdb_0198 | PEPTIDE NAMEBacteriophage derive | PEPTIDE SEQUENCE (1-letter)SRYSIGGNNGVT | PEPTIDE SEQUENCE (3-letter)SerArgTyrSerIleGlyGlyAsnAsnGlyValThr | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH12 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDET7 Bacteiophage derived | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELMale wistar mice | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONCan cross BBB as well as Blood CSF barrier | TRANSPORT TYPETransendocytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONAlzheimer | RESPONSENA | RESULTNA | LABELNA | PMID 26411801 |
| B3pdbIDb3pdb_0202 | PEPTIDE NAMEBacteriophage derive | PEPTIDE SEQUENCE (1-letter)RSTASTSYPFFF | PEPTIDE SEQUENCE (3-letter)ArgSerThrAlaSerThrSerTyrProPhePhePhe | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH12 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDET7 Bacteiophage derived | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELMale wistar mice | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONCan cross BBB as well as Blood CSF barrier | TRANSPORT TYPETransendocytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONAlzheimer | RESPONSENA | RESULTNA | LABELNA | PMID 26411801 |
| B3pdbIDb3pdb_0203 | PEPTIDE NAMEBacteriophage derive | PEPTIDE SEQUENCE (1-letter)YAWGGGWVLQWF | PEPTIDE SEQUENCE (3-letter)TyrAlaTrpGlyGlyGlyTrpValLeuGlnTrpPhe | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH12 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDET7 Bacteiophage derived | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELMale wistar mice | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONCan cross BBB as well as Blood CSF barrier | TRANSPORT TYPETransendocytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONAlzheimer | RESPONSENA | RESULTNA | LABELNA | PMID 26411801 |
| B3pdbIDb3pdb_0204 | PEPTIDE NAMEBacteriophage derive | PEPTIDE SEQUENCE (1-letter)DAAESVLVGTVR | PEPTIDE SEQUENCE (3-letter)AspAlaAlaGluSerValLeuValGlyThrValArg | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH12 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDET7 Bacteiophage derived | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELMale wistar mice | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONCan cross BBB as well as Blood CSF barrier | TRANSPORT TYPETransendocytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONAlzheimer | RESPONSENA | RESULTNA | LABELNA | PMID 26411801 |
| B3pdbIDb3pdb_0205 | PEPTIDE NAMEBacteriophage derive | PEPTIDE SEQUENCE (1-letter)ISNRSHKGLMVG | PEPTIDE SEQUENCE (3-letter)IleSerAsnArgSerHisLysGlyLeuMetValGly | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH12 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDET7 Bacteiophage derived | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELMale wistar mice | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONCan cross BBB as well as Blood CSF barrier | TRANSPORT TYPETransendocytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONAlzheimer | RESPONSENA | RESULTNA | LABELNA | PMID 26411801 |
| B3pdbIDb3pdb_0206 | PEPTIDE NAMEBacteriophage derive | PEPTIDE SEQUENCE (1-letter)YNQSLLQGYRYW | PEPTIDE SEQUENCE (3-letter)TyrAsnGlnSerLeuLeuGlnGlyTyrArgTyrTrp | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH12 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDET7 Bacteiophage derived | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELMale wistar mice | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONCan cross BBB as well as Blood CSF barrier | TRANSPORT TYPETransendocytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONAlzheimer | RESPONSENA | RESULTNA | LABELNA | PMID 26411801 |
| B3pdbIDb3pdb_0208 | PEPTIDE NAMEBacteriophage derive | PEPTIDE SEQUENCE (1-letter)MRWFFSHASQGR | PEPTIDE SEQUENCE (3-letter)MetArgTrpPhePheSerHisAlaSerGlnGlyArg | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH12 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDET7 Bacteiophage derived | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELMale wistar mice | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONCan cross BBB as well as Blood CSF barrier | TRANSPORT TYPETransendocytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONAlzheimer | RESPONSENA | RESULTNA | LABELNA | PMID 26411801 |
| B3pdbIDb3pdb_0209 | PEPTIDE NAMEBacteriophage derive | PEPTIDE SEQUENCE (1-letter)RLSSVDSDLSGC | PEPTIDE SEQUENCE (3-letter)ArgLeuSerSerValAspSerAspLeuSerGlyCys | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH12 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDET7 Bacteiophage derived | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELMale wistar mice | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONCan cross BBB as well as Blood CSF barrier | TRANSPORT TYPETransendocytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONAlzheimer | RESPONSENA | RESULTNA | LABELNA | PMID 26411801 |
| B3pdbIDb3pdb_0210 | PEPTIDE NAMEBacteriophage derive | PEPTIDE SEQUENCE (1-letter)GRPQKINGARVC | PEPTIDE SEQUENCE (3-letter)GlyArgProGlnLysIleAsnGlyAlaArgValCys | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH12 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDET7 Bacteiophage derived | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELMale wistar mice | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONCan cross BBB as well as Blood CSF barrier | TRANSPORT TYPETransendocytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONAlzheimer | RESPONSENA | RESULTNA | LABELNA | PMID 26411801 |
| B3pdbIDb3pdb_0212 | PEPTIDE NAMEBacteriophage derive | PEPTIDE SEQUENCE (1-letter)KVAWRVFSLFWK | PEPTIDE SEQUENCE (3-letter)LysValAlaTrpArgValPheSerLeuPheTrpLys | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH12 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDET7 Bacteiophage derived | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELMale wistar mice | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONCan cross BBB as well as Blood CSF barrier | TRANSPORT TYPETransendocytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONAlzheimer | RESPONSENA | RESULTNA | LABELNA | PMID 26411801 |
| B3pdbIDb3pdb_0213 | PEPTIDE NAMEBacteriophage derive | PEPTIDE SEQUENCE (1-letter)GFVRFRLSNTR | PEPTIDE SEQUENCE (3-letter)GlyPheValArgPheArgLeuSerAsnThrArg | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH11 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDET7 Bacteiophage derived | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELMale wistar mice | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONCan cross BBB as well as Blood CSF barrier | TRANSPORT TYPETransendocytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONAlzheimer | RESPONSENA | RESULTNA | LABELNA | PMID 26411801 |
| B3pdbIDb3pdb_0233 | PEPTIDE NAMEProtamine | PEPTIDE SEQUENCE (1-letter)VSRRRRRRGGRRRR | PEPTIDE SEQUENCE (3-letter)ValSerArgArgArgArgArgArgGlyGlyArgArgArgArg | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH13 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEDerived from protamine | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION10 microliter per nostril | In vivo MODE OF DELIVERYIntranasal | In vivo METHODIn vivo imaging | In vivo RESULTPeptide + BSA combination deleiveerd in brain olfactory bulb and littlebit in cerebral | ACTIONpeptide can deliver drug into brain tissue | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONPeptide+BSA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 27471676 |
| B3pdbIDb3pdb_0234 | PEPTIDE NAMEPepH1 | PEPTIDE SEQUENCE (1-letter)VQQLTKRFSL | PEPTIDE SEQUENCE (3-letter)ValGlnGlnLeuThrLysArgPheSerLeu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH14 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEDerived from dengue virus capsid | SMILESNA | CELL LINEbEND cell line | In vitro CONCENTRATION5 microCi/ml | In vitro METHODGamma counter radioactivity measure for TcPz | In vitro RESULT73.83+/- 9.40 | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONCan cross blood brain barrier as well as shows membrane adsorption | TRANSPORT TYPETransmigration | SUBCELLULAR LOCALISATIONCan be migrated to liver, kidney etc. | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 28263555 |
| B3pdbIDb3pdb_0236 | PEPTIDE NAMEPepH3 | PEPTIDE SEQUENCE (1-letter)AGILKRW | PEPTIDE SEQUENCE (3-letter)AlaGlyIleLeuLysArgTrp | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH14 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEDerived from dengue virus capsid | SMILESNA | CELL LINEbEND cell line | In vitro CONCENTRATION5 microCi/ml | In vitro METHODGamma counter radioactivity measure for TcPz | In vitro RESULT67.33+/- 1.20 | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONCan cross blood brain barrier as well as shows membrane adsorption | TRANSPORT TYPETransmigration | SUBCELLULAR LOCALISATIONCan be migrated to liver, kidney etc. | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 28263555 |
| B3pdbIDb3pdb_0238 | PEPTIDE NAMEPepH1 | PEPTIDE SEQUENCE (1-letter)VQQLTKRFSL | PEPTIDE SEQUENCE (3-letter)ValGlnGlnLeuThrLysArgPheSerLeu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH14 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEDerived from dengue virus capsid | SMILESNA | CELL LINEbEND cell line | In vitro CONCENTRATION5 microCi/ml | In vitro METHODGamma counter radioactivity measure for gaNODA | In vitro RESULT71.47+/- 3.70 | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONCan cross blood brain barrier as well as shows membrane adsorption | TRANSPORT TYPETransmigration | SUBCELLULAR LOCALISATIONCan be migrated to liver, kidney etc. | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 28263555 |
| B3pdbIDb3pdb_0240 | PEPTIDE NAMEPepH3 | PEPTIDE SEQUENCE (1-letter)AGILKRW | PEPTIDE SEQUENCE (3-letter)AlaGlyIleLeuLysArgTrp | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH14 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEDerived from dengue virus capsid | SMILESNA | CELL LINEbEND cell line | In vitro CONCENTRATION5 microCi/ml | In vitro METHODGamma counter radioactivity measure for gaNODA | In vitro RESULT72.63 +/- 0.70 | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONCan cross blood brain barrier as well as shows membrane adsorption | TRANSPORT TYPETransmigration | SUBCELLULAR LOCALISATIONCan be migrated to liver, kidney etc. | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 28263555 |